These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 1278088)

  • 21. [Medical management and social status of elderly Parkinson patients].
    Vieregge P; Körtke D; Meyer-Bornsen C
    Z Gerontol; 1994; 27(4):260-9. PubMed ID: 7975817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of cirrhotic hepatic encephalopathy with L-dopa. A controlled trial.
    Michel H; Solere M; Granier P; Cauvet G; Bali JP; Pons F; Bellet-Hermann H
    Gastroenterology; 1980 Aug; 79(2):207-11. PubMed ID: 6995221
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis.
    Merello M; Nouzeilles MI; Arce GP; Leiguarda R
    Mov Disord; 2002 Jul; 17(4):795-8. PubMed ID: 12210878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [L-dopa + peripheral decarboxylase antagonist].
    Wiesel FA
    Lakartidningen; 1975 Oct; 72(43):4173. PubMed ID: 1177632
    [No Abstract]   [Full Text] [Related]  

  • 25. [Trans-cerebral electrophoresis of L-DOPA in the complex treatment of parkinsonism].
    Neĭmark EZ; Evtushenko SK; Dukhovnaia MA
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1984; 84(9):1334-8. PubMed ID: 6506979
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Value of the probenecid test in the diagnosis and treatment of parkinson disease].
    Vanderheyden JE; Noel G; Mendlewicz J
    Acta Neurol Belg; 1982; 82(6):339-52. PubMed ID: 7164768
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Parosmia and anosmia under L-dopa therapy (author's transl)].
    Neundörfer B; Valdivieso T
    Nervenarzt; 1977 May; 48(5):283-4. PubMed ID: 895952
    [No Abstract]   [Full Text] [Related]  

  • 28. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
    Kanda T; Jackson MJ; Smith LA; Pearce RK; Nakamura J; Kase H; Kuwana Y; Jenner P
    Exp Neurol; 2000 Apr; 162(2):321-7. PubMed ID: 10739638
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pharmacokinetic and pharmacodynamic aspects of L-DOPA treatment and dopadecarboxilase inhibitors and dopaminergic antagonists in Parkinson's disease (author's transl)].
    García de Yébenes J; Avila C; Bazán E; García E; Gervás J; Maseda C; Mena M; Muradas V; Ramos JA
    Med Clin (Barc); 1982 Apr; 78(7):259-64. PubMed ID: 7087591
    [No Abstract]   [Full Text] [Related]  

  • 30. [Psychological changes in parkinsonian patients during L-DOPA, amantidine, and L-DOPA + IDC treatment (author's transl)].
    Puca FM; Megna GF; Masi G; Specchio LM
    Riv Patol Nerv Ment; 1974 Oct; 95(5):676-84. PubMed ID: 4470268
    [No Abstract]   [Full Text] [Related]  

  • 31. [Letter: A severe case of postural hypotension. Paradoxical treatment by L-dopa combined with an inhibitor of extracerebral dopa-decarboxylase].
    Boismare F; Boquet J
    Nouv Presse Med; 1975 Feb; 4(8):589. PubMed ID: 1129119
    [No Abstract]   [Full Text] [Related]  

  • 32. [Positive effects of L-dopa on a "marginal" symptomatology observed in parkinsonians].
    Morel-Maroger A
    Encephale; 1978; 4(3):223-31. PubMed ID: 309387
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Parkinson syndrome, frontal tumor and L-dopa].
    Lhermitte F; Agid Y; Serdaru M; Guimaraes J
    Rev Neurol (Paris); 1984; 140(2):138-9. PubMed ID: 6710014
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dopa-responsive dystonia. Delineation of the clinical syndrome and clues to pathogenesis.
    Nygaard TG
    Adv Neurol; 1993; 60():577-85. PubMed ID: 8420194
    [No Abstract]   [Full Text] [Related]  

  • 35. L-DOPA: from a biologically inactive amino acid to a successful therapeutic agent.
    Hornykiewicz O
    Amino Acids; 2002; 23(1-3):65-70. PubMed ID: 12373520
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
    Rioux L; Frohna PA; Joyce JN; Schneider JS
    Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Acute psychoses and mood disorders in Parkinson disease. Role of antiparkinson therapy].
    Mouren P; Poinso Y; Oppenheim G; Mouren A; Nguyen Quang N
    Ann Med Psychol (Paris); 1983; 141(8):843-57. PubMed ID: 6666915
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peripheral aromatic L-amino acids decarboxylase inhibitor in Parkinsonism. I. Effect on O-methylated metabolites of L-dopa-2- 14 C.
    Messiha FS; Hsu TH; Bianchine JR
    J Clin Invest; 1972 Feb; 51(2):452-5. PubMed ID: 5009125
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treatment of Parkinson's disease with L-dopa and with a combination of L-dopa and dopa-decarboxylase inhibitor].
    Agnoli A; Casacchia M; Reitano M; Ruggieri S; Barba C; Zamponi A
    Minerva Med; 1972 Dec; 63(89):4853-61. PubMed ID: 4566743
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.